United Therapeutics-2026-JPM- Corporation.pdf

1、United Therapeutics CorporationJ.P.Morgan Healthcare ConferenceJANUARY 12,20262Safe Harbor StatementUTHR:A Public Benefit CorporationMIROKIDNEY,MIROLIVER,MIROLIVERELAP,ORENITRAM,REMODULIN,TYVASO,TYVASO DPI,and UNITUXIN are registered trademarks of United Therapeutics Corporation and/or its subsidiar

2、ies.UHEART,UKIDNEY,ULOBE,ULUNG,UTHYMOKIDNEY,and REMUNITYPRO are trademarks of United Therapeutics Corporation and/or its subsidiaries.ADCIRCA is a registered trademark of Eli Lilly and Company.All statements in this presentation are made as of January 12,2026.We undertake no obligation to publicly u

3、pdate or revise these statements,whether as a result of new information,future events,or otherwise.Statements included in this presentation that are not historical in nature are“forward-looking statements”within the meaning of the Private Securities Litigation Reform Act of 1995.Forward-looking stat

4、ements include,among others,statements related to our revenue growth expectations,the timing and success of our pipeline programs,our planned manufacturing and field force expansions,our organ manufacturing efforts,and similar statements concerning anticipated future events and expectations.We cauti

5、on you that these statements are not guarantees of future performance and are subject to numerous evolving risks and uncertainties that we may not be able to accurately predict or assess,including the risk factors that we describe in our Securities and Exchange Commission filings,including our most

6、recent Annual Report on Form 10-K or Quarterly Report on Form 10-Q.Any of these factors could cause actual results to differ materially from the expectations we express or imply in this presentation.This presentation and any related discussions or statements are intended to educate investors about o